Soo Paulo Med J 2005, ALK inhibitor drugs 123:192–197. 14. Pohlreich P, Zikan M, Stribrna J, Kleib Z, Janatova M, Kotlas J: High proportion of recurrent
gremline mutations in the BRCAl gene in selleck breast and ovarian cancer patients from the Prague area. Breast cancer research 2005, 7:R728-R736.PubMedCrossRef 15. Easton DF, Bishop T, Ford D, Crockford GP: Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. Am J Hum Genet 1993, 52:678–701.PubMed 16. Peelen T, Van Vliet M, Petrij-Bosch R: A high proportion of novel mutations in BRCAl with strong founder effects among Dutch and Belgian hereditary breast and ovarian cancer families. Am J Hum Genet 1997, 60:1041–1049.PubMed 17. Hamann U, Brauch H, Garvin AM, Bastert G, Scott RJ: German family study on hereditary breast and/or ovarian cancer; germline mutation analysis of the BRCAl gene. Genes chromosomes cancer 1997, 18:126–132.PubMedCrossRef 18. Friedman S, Ostermeyer A, Szabo I, Dowd P, Lynch D: Confirmation Of
BRCA1 Analysis Of Germline Mutations Linked To Breast And Ovarian Cancer In Ten Families. Naturegenet 1994, 8:399–404. 19. Ramus J, Kote-Jarai Z, Van Der Looij M, Gayther S, Csokay B, Ponder J: Analysis Of BRCA1 And BRC2 Mutations In Hungarian Families With Breast And Breast- Ovarian Cancer. Amer J Hum Genet 1997b, 60:1242–1246. 20. Blackwood MA, Weber BL: BRCA1 and BRCA2: from molecular genetics to clinical medicine. J Clin Oncol 1998, 16:1969–1977.PubMed 21. Dite GS, Jenkins MA, Southey MC: Familial risks, early-onset breast cancer, and BRCA1 and BRCA2 germline mutations. J Natl Cancer Inst 2003, 95:448–457.PubMedCrossRef AR-13324 solubility dmso 22. Loman N, Bladstrom A, Johannsson O, Borg A, Osson H: Cancer incidence in relatives of a population-based set of cases
of early- onset breast cancer with a known BRCA1 and BRCA2 mutation status. Breast cancer Res 2003, 5:R175-R186.PubMedCrossRef 23. Lallor F, Varley J, Ellis P, Moran A, O’Dair L, Pharoah P: The early onset breast cancer study group: Prediction of pathogenic mutations in patients with early-onset breast cancer by family history. Lancet 2003, 361:1101–1102.CrossRef 24. Diez O, Cories J, Domenech M, Brunet J, Delrio 3-oxoacyl-(acyl-carrier-protein) reductase E, Pericay C: BRCAl mutation analysis in 83 spanish- breast and/ovarian cancer families. Int J Cancer 1999, 83:465–469.PubMedCrossRef 25. Walsh T, Casadei S, Coats KH, Swisher E, Stray SM: Spectrum of Mutations in BRCAl, CHEK2 and TP53 in families at high risk of breast cancer. JAMA 2006, 295:1379–1388.PubMedCrossRef 26. Neuhausen SL: Ethnic differences in cancer risk resulting from genetic variation. Cancer 1999,86(Suppl 11):2575–2582.PubMedCrossRef 27. Dorum A, Hovig E, Trope C, Inganas M, Moller P: Three percent of Norwegian ovarian cancers are caused by BRCAl 1675 del A or 1135 ins A. Eur J Cancer 1999, 35:779–781.PubMedCrossRef 28.